Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Blood (2024) 144 (Supplement 1): 639.

https://doi.org/10.1182/blood-2024-200415

Published: 2024

Journal Articles

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Blood (2023) 142 (Supplement 1): 836.

https://doi.org/10.1182/blood-2023-180336

Published: 2023

Journal Articles

Prognostic Impact of Chromosomal Abnormalities in TP53 -Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2023-180291

Published: 2023

Journal Articles

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2023-185857

Published: 2023

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia C. Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro Marshall Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 208–210.

https://doi.org/10.1182/blood-2022-158851

Published: 2022

Journal Articles

Risk Stratification of Diffuse Large B-Cell Lymphoma Based on Cell Surface Markers Using Flow Cytometry

Tomoyo Kubo, Yoshimitsu Shimomura, Hayato Maruoka, Yuya Nagai, Tadakazu Kondo, Takayuki Ishikawa

Blood (2022) 140 (Supplement 1): 3842–3843.

https://doi.org/10.1182/blood-2022-162248

Published: 2022

Journal Articles

The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19

Masashi Nishikubo, Yoshimitsu Shimomura, Yuya Nagai, Tadakazu Kondo, Takayuki Ishikawa

Blood (2022) 140 (Supplement 1): 11195–11196.

https://doi.org/10.1182/blood-2022-166433

Published: 2022

Journal Articles

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 3663–3665.

https://doi.org/10.1182/blood-2022-168696

Published: 2022

Journal Articles

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Blood (2022) 140 (Supplement 1): 6902–6904.

https://doi.org/10.1182/blood-2022-168213

Published: 2022

Journal Articles

Booster Dose of mRNA-Based COVID-19 Vaccine Induces a Humoral and Cellular Response in Patients Recently Treated with Anti-CD20 Monoclonal Antibodies

Masashi Nishikubo, Yoshimitsu Shimomura, Ryusuke Yamamoto, Hayato Maruoka, Seiko Nasu, Tomomi Nishioka, Kenji Sakizono, Satoshi Mitsuyuki, Tomoyo Kubo, Naoki Okada, Daishi Nakagawa, Kimimori Kamijo, Hiroharu Imoto, Yuya Nagai, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Tadakazu Kondo, Takayuki Ishikawa

Blood (2022) 140 (Supplement 1): 2633–2634.

https://doi.org/10.1182/blood-2022-162172

Published: 2022

Journal Articles

Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies

Blood (2021) 138 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2021-149403

Published: 2021

Journal Articles

EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia

Blood (2021) 138 (Supplement 1): 610.

https://doi.org/10.1182/blood-2021-152800

Published: 2021

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia

June Takeda, MD, Kenichi Yoshida, MDPhD, Akinori Yoda, PhD, Lee-Yung Shih, MD, Yasuhito Nannya, MD PhD, Yotaro Ochi, MD, Ayana Kon, MD PhD, Kenichi Chiba, Yuichi Shiraishi, PhD, Yusuke Shiozawa, MD PhD, Tetsuichi Yoshizato, MD PhD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Toshiyuki Kitano, MD PhD, Akira Hangaishi, MD PhD, Ken Ishiyama, MD PhD, Hisashi Tsurumi, MD PhD, Yasushi Miyazaki, MD PhD, Nobuhiro Hiramoto, MD, Takayuki Ishikawa, MD PhD, Masahiro Marshall Nakagawa, MDPhD, Akifumi Takaori-Kondo, MD PhD, Shigeru Chiba, MD PhD, Hideyuki Nakazawa, MD PhD, Ming-Chung Kuo, MD, Keisuke Kataoka, MD PhD, Ryunosuke Saiki, MD, Hiroko Tanaka, Kensuke Usuki, MD PhD, Shuichi Miyawaki, MD PhD, Satoru Miyano, PhD, Jaroslaw P. Maciejewski, MD PhD, Arnold Ganser, Michael Heuser, Prof., MD, Felicitas Thol, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-141750

Published: 2020

Journal Articles

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136145

Published: 2020

Journal Articles

Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140629

Published: 2020

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Yoshimitsu Shimomura, Masahiko Hara, MD PhD, Hisashi Yamamoto, MD PhD, Tatsuo Ichinohe, Takahiro Fukuda, Minoko Takanashi, MD PhD, Yoshiko Atsuta, MD PhD, Takayuki Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 254.

https://doi.org/10.1182/blood-2019-125470

Published: 2019

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

NARROW

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Prognostic Impact of Chromosomal Abnormalities in TP53 -Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Risk Stratification of Diffuse Large B-Cell Lymphoma Based on Cell Surface Markers Using Flow Cytometry

The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Booster Dose of mRNA-Based COVID-19 Vaccine Induces a Humoral and Cellular Response in Patients Recently Treated with Anti-CD20 Monoclonal Antibodies

Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies

EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia

Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only